Bio‑Rad (BIO) EVP Eva Engelhardt Receives 246-Share RSU Award

What Happened
Eva Anette Engelhardt, EVP and President of the Clinical Diagnostics Group at Bio‑Rad Laboratories (BIO), had 246 restricted stock units (RSUs) convert into 246 Class A shares on 2026-07-25 (reported on a Form 4 filed 2026-07-28). The filing shows 89 of those shares were withheld to satisfy tax withholding at $314.46 per share (89 × $314.46 = $27,987). The gross value of the 246 vested shares was about $77,357, leaving a net delivery of 157 shares to Engelhardt (157 × $314.46 ≈ $49,370). This was a vesting/award event rather than an open-market purchase or sale.

Key Details

• Transaction date: 2026-07-25; Form 4 filed: 2026-07-28 (no late-filing flag indicated).
• Transaction codes: M = conversion/exercise of a derivative (RSU conversion to shares); F = shares withheld for tax payment.
• Shares vested/converted: 246; shares withheld for taxes: 89 at $314.46/share = $27,987; net shares delivered: 157 (net value ≈ $49,370).
• Acquisition price shown as $0.00 because these were RSUs vesting (see footnotes).
• Shares owned after the transaction: not specified in the excerpt of the filing provided.
• Relevant footnotes from the filing: F1 — shares acquired on vesting of RSUs; F2 — each RSU equals a right to one share; F3 — RSUs vest over four years at 25% per year.

Context
This was a routine equity compensation vesting event (not an open-market buy or sale). The tax liability was satisfied by withholding shares (a common practice sometimes called a cashless/net settlement). For retail investors, RSU vesting shows executive compensation being realized but does not by itself indicate a change in the insider’s market view.